🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
In this study, the efficacy and safety of two nilotinib doses, 300 mg twice...
Status
Completed
Location
University of California at Los Angeles Dept. of Hematology Clinic
Start Date
2007-07-31
Trial ID
NCT00471497
The suppression of the immune system creates a permissive environment for d...
Status
Unknown
Location
Multiple Locations
Start Date
2017-08-05
Trial ID
NCT03214718
Maintain and monitor long-term hematological and cytogenetic responses prev...
Status
Completed
Location
Novartis Investigative Site
Start Date
2008-08
Trial ID
NCT00786812
Treatments Being Tested
The purpose of this prospective, single-institution observational study is ...
Status
Completed
Location
UNC Hospital
Start Date
2019-06-20
Trial ID
NCT03885830
This pilot clinical trial studies the feasibility of choosing treatment bas...
Status
Completed
Location
Fred Hutch/University of Washington Cancer Consortium
Start Date
2015-09-11
Trial ID
NCT02551718
Background: Advanced urothelial cancer has no cure. But only a few chemoth...
Status
Completed
Location
National Institutes of Health Clinical Center
Start Date
2017-03-27
Trial ID
NCT02788201
Treatments Being Tested
The purpose of this trial is to assess the effect of switching CML patients...
Status
Terminated
Location
Aarhus University Hospital
Start Date
2013-04
Trial ID
NCT01866553
Treatments Being Tested
In this study, the efficacy of nilotinib at 400 mg BID will be compared wit...
Status
Unknown
Location
Seoul St. Mary's Hospital
Start Date
2009-01
Trial ID
NCT01400074
Treatments Being Tested
The extension study followed the core study CAMN107ECN02 (NCT01275196). whi...
Status
Completed
Location
Novartis Investigative Site
Start Date
2014-07-17
Trial ID
NCT02272777
To evaluate the major molecular response (MMR) rate at 12 months of nilotin...
Status
Completed
Location
Novartis Investigative Site
Start Date
2009-12
Trial ID
NCT01043874
Treatments Being Tested